N/A N=228 Proton Therapy for Low and Intermediate Risk Prostate Cancer
Prostate Cancer
Primary: Acute Grade 3 (NCI CTC v4.0) or Higher Treatment-related Toxicity Rate. — 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=101 A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer
Prostate Cancer
Primary: MP-erMRI Classification Sensitivity — 0.875 proportion of true positives
Early Phase 1 N=19 Intensity Modulated Radiation Therapy for Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Any Grade 2 Toxicity Using Intensity Modulated Radiation Therapy (IMRT) to Treat the At-risk Lymph Nodes in Prostate Cancer ( up to First 10…
N/A N=22 PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer
Metastatic Prostate Cancer
Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants
Phase 2 N=56 Hypofractionation Proton Beam Therapy With Concurrent Treatment of Prostate and Pelvic Nodes for Prostate Cancer
Prostate Cancer
Primary: Late Grade ≥ 3 Gastrointestinal (GI) and Genitourinary (GU) Toxicity of Interest, Using the CTCAE v4.0 — 1; 0 Participants
N/A N=35 High-Dose Stereotactic Radiation for Prostate Cancer
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer · Stage I Prostate Cancer
Primary: Number of Patients With Treatment Related GI and/or GU Toxicity as Assessed by the NCI CTCTAE Version 4.0 — 1 Participants
Phase 2 N=27 Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
Prostate Cancer
Primary: Percentage of Patients Who Can Safely Tolerate and Complete Adjuvant Hormonal Therapy, Radiation Therapy and Docetaxel After a Radical Prostatectomy — 26 percentage of…
N/A N=83 CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer
Prostate Adenocarcinoma
Primary: Biochemical Disease-Free Survival (bDFS), Using Phoenix and ASTRO Definitions — 46; 27; 45; 27 Participants
N/A N=30 VMAT for Dominant Intraprostatic Lesion
Prostate Cancer
Primary: Number of Participants With Biochemical Failure at 5 Years — 0; 30 Participants
N/A N=84 Hypofractionated Accelerated Radiotherapy for Low Risk Localized Prostate Cancer
Prostate Cancer
Primary: Incidence of Grade 3+ Gastrointestinal Toxicity — 0 participants
Phase 3 N=731 Prostate Cancer Intervention Versus Observation Trial (PIVOT)
Prostate Cancer
Primary: All Cause Mortality — 171; 183 Participants
Phase 2 N=75 Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Prostate Adenocarcinoma · Prostate Cancer · High Risk Prostate Cancer
Primary: Percentage of Participants With Pathologic Complete Response (pCR) or Minimal Residual Disease (MRD) — 30; 16 percentage of participants — p=0.151
Phase 3 N=1,532 Radiation Therapy in Treating Patients With Stage II Prostate Cancer
Prostate Cancer
Primary: Overall Survival — 88.5; 88.1 percentage of participants — p=0.98
Phase 2 N=80 Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
Prostate Cancer
Primary: Number of Participants Free From Progression at 3 Years — 54 participants
Phase 3 N=115 A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Negative Biopsies at Month 12 — 28; 17 Participants — p=0.0318
N/A N=35 Optimizing Active Surveillance in Low-Risk Prostate Cancer: a Pilot Study
Prostate Cancer
Primary: Feasibility - Recruitment — 39 Participants
N/A N=163 Hypofractionated SBRT For Prostate Cancer
Prostate Cancer
Primary: Rate of Acute Grade 3 or Higher GI and GU Toxicities — 2 Participants
Phase 2 N=15 MR Image Guided Therapy in Prostate Cancer
Prostate Cancer · Prostatic Neoplasms
Primary: Number of Participants With One Grade 1 Adverse Event, More Than One Grade 1 Adverse Event, and One Grade 2 Adverse Event — 4; 2; 4 Participants
N/A N=101 Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions
Localized Intermediate Risk Prostate Lesions
Primary: Number of Device and Procedure Related Adverse Events — 24 Number of Adverse Events
Phase 2 N=28 Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
Newly Diagnosed Oligometastatic Prostate Cancer
Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants
Phase 4 N=226 A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
Prostate Cancer
Primary: Number of Subjects With BR Events — 35; 26 Participants
N/A N=77 Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer
Prostate Cancer
Primary: Acute Grade 3 or Higher Treatment-related Toxicity Rate. — 1; 3 participants — p=<0.0001
Phase 1 N=17 Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
Prostate Cancer · Prostatic Neoplasm
Primary: Maximum Tolerated Dose (MTD) — 40; 42.5 gray (Gy)
Phase 2 N=53 Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy
Prostate Adenocarcinoma · Stage IIB Prostate Cancer AJCC v8 · Stage III Prostate Cancer AJCC v8
Primary: Freedom From Failure (FFF) — 7; 16; 5 Participants
Phase 3 N=1,115 Radiation Therapy in Treating Patients With Stage II Prostate Cancer
Prostate Cancer
Primary: Five-year Disease-free Survival (DFS) Rate — 85.3; 86.3 percentage of participants — p=<0.001
Phase 2 N=32 Sequential Vaccinations in Prostate Cancer Patients
Prostatic Neoplasms
Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants
N/A N=25 MRI- Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer
MRI Guided Transurethral Ultrasound Ablation · Localized Prostate Cancer · Ablation Therapy
Primary: Absence of Clinically Significant Cancer (CSC) on Control Biopsy at 1-year Follow-up. — 8 Participants
N/A N=116 Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate Cancer
Prostate Cancer · Sexual Dysfunction · Sexuality and Reproductive Issues
Primary: Erectile Dysfunction Rates — 27; 36 Participants
Phase 2 N=36 PSMA-PET for Biopsy and Treatment Guidance in Primary Prostate Cancer
Prostate Cancer
Primary: Diagnostic Accuracy of PSMA PET — 100; 74 percentage
Phase 2 N=27 Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Dose Limiting Toxicities (Phase I and Safety Run-In) — 0; 0 Participants